Baseline characteristics of the treated cohorts
| Surgery | SABR | CFRT | p-value | |
| Subjects | 316 | 99 | 53 | |
| Age years | 69.9 (57.12–82.7) | 76.7 (63.5–90.0) | 76.5 (63.8–89.3) | |
| Age group years | ||||
| 30–59 | 47 (14.87) | 4 (4.04) | 0 (0.00) | <0.001 |
| 60–69 | 112 (35.44) | 21 (21.21) | 12 (22.64) | |
| 70–79 | 127 (40.19) | 42 (42.42) | 20 (37.74) | |
| ≥80 | 30 (9.49) | 32 (32.32) | 21 (39.62) | |
| Female | 176 (55.70) | 44 (44.44) | 30 (56.60) | 0.050 |
| Histology | ||||
| Squamous cell | 95 (30.06) | 21 (21.21) | 16 (30.19) | <0.001 |
| Other | 215 (68.04) | 35 (35.35) | 17 (32.08) | |
| Benign | 5 (1.58) | 0 (0.00) | 0 (0.00) | |
| Unknown | 1 (0.32) | 43 (43.43) | 20 (37.74) | |
| Pre-operative stage | ||||
| IA | 197 (62.34) | 68 (68.69) | 23 (43.40) | 0.252 |
| Post-operative stage | ||||
| IA | 140 (44.30) | |||
| IB | 107 (33.86) | |||
| IIA | 36 (11.39) | |||
| IIB | 17 (5.38) | |||
| IIIA | 9 (2.85) | |||
| IIIB | 1 (0.32) | |||
| IV | 1 (0.32) | |||
| Benign | 5 (1.58) | |||
| WHO performance status | ||||
| 0–1 | 263 (83.23) | 41 (41.41) | 17 (32.08) | <0.001 |
| 2 | 45 (14.24) | 29 (29.29) | 20 (37.74) | |
| 3–4 | 8 (2.53) | 29 (29.29) | 16 (30.19) | |
| Year | ||||
| 2008 | 55 (17.41) | 0 (0.00) | 9 (16.98) | <0.001 |
| 2009 | 51 (16.14) | 8 (8.08) | 6 (11.32) | |
| 2010 | 46 (14.56) | 19 (19.19) | 13 (24.53) | |
| 2011 | 54 (17.09) | 30 (30.30) | 7 (13.21) | |
| 2012 | 72 (22.78) | 28 (28.28) | 14 (26.42) | |
| 2013 | 38 (12.03) | 14 (14.14) | 4 (7.55) |
Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. SABR: stereotactic ablative body radiotherapy; CFRT: conventionally fractionated radiotherapy; WHO: World Health Organization. Histological subtype was not significantly different between the cohorts when those without histological confirmation were excluded (p=0.379). p-values represent the comparison between surgery and SABR.